Cipla launches Yurpeak (tirzepatide) for the treatment of obesity and type 2 diabetes in India

Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors

Cipla opens India's First dedicated lung health diagnostics center in Delhi

Cipla to acquire Inzpera Healthsciences for Rs. 110.65 Cr

The transaction is expected to be completed within one month from the signing of the definitive agreements.

Cipla posts consolidated Q2 FY26 PAT Rs. 1,351.17 Cr

Cipla has reported total income of Rs. 7,858.39 crore during the period ended September 30, 2025

Cipla to sell Lilly's weight-loss drug under new brand in India

Tirzepatide is a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors

Briefs: Nectar Lifesciences, Cipla and Marksans Pharma

Marksans Pharma gets USFDA nod for acid reflux drug

Cipla reports Q1 FY2025-26 consolidated profit up at Rs. 1,297.62 Cr

Cipla has reported total income of Rs. 7,216.03 crores during the period ended June 30, 2025

Cipla to invest in iCaltech to strengthen respiratory play

iCaltech is engaged in the design, development, and commercialisation of diagnostic medical equipment and apparatus

Cipla appoints Prabhakaran Balakrishnan Nair as Global Chief Manufacturing Officer

Cipla reports FY25 PAT higher 28.4% at Rs. 5,273 Cr

The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore